Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GB-0895

Other · developed by Generate Biomedicines

Phase 3 Most advanced trial
GENB Developer
2 Registered trials

What is GB-0895?

GB-0895 is a drug given by subcutaneous injection, studied in asthma and chronic obstructive pulmonary disease (COPD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Generate Biomedicines (GENB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07276724 Phase 3 Severe Asthma Recruiting GENB
NCT07116889 Phase 1 Asthma Active not recruiting GENB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AsthmaCOPD (Chronic Obstructive Pulmonary Disease)Severe Asthma

More from Generate Biomedicines

GB-0669 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GENB page.

Follow GENB, the company behind GB-0895

See GENB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GENB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.